HeartBeam Secures $10 Million in Public Offering to Accelerate Cardiac Technology Deployment

HeartBeam Inc. (NASDAQ: BEAT) has closed an underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, will fund the commercialization of the company’s FDA-cleared 12-lead synthesized ECG system and further development of its extended-wear patch and heart attack detection technologies.

The capital infusion will support expansion of artificial intelligence capabilities and general corporate purposes, according to the company’s announcement. The offering received support from key stakeholders including ClearCardio(TM), company leadership and institutional investors. This financial milestone comes as HeartBeam prepares to bring its innovative cardiac monitoring technology to broader markets.

HeartBeam is developing what it describes as the first-ever cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing those signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever patients are located, delivering what the company calls ‘actionable heart intelligence.’ The technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. Additional details about the cleared indications for use are available at https://www.heartbeam.com/indications.

The company’s approach aims to enable physicians to identify cardiac health trends and acute conditions while directing patients to appropriate care outside traditional medical facilities. HeartBeam holds over 20 issued patents related to its technology enablement. The company maintains a newsroom where investors can access the latest updates and information at https://ibn.fm/BEAT.

This funding round represents a significant step toward making advanced cardiac monitoring more accessible outside clinical settings. The technology’s potential to transform how cardiac conditions are detected and monitored could have substantial implications for patient care, particularly for those who require ongoing cardiac assessment but face barriers to frequent medical facility visits. The development of extended-wear patches and enhanced AI capabilities suggests a move toward more continuous, comprehensive cardiac monitoring solutions that could provide earlier detection of potentially life-threatening conditions.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is HeartBeam Secures $10 Million in Public Offering to Accelerate Cardiac Technology Deployment.

The post HeartBeam Secures $10 Million in Public Offering to Accelerate Cardiac Technology Deployment appeared first on citybuzz.